Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 67

1.

Trends in hepatocyte growth factor, insulin-like growth factor 1, thyroid-stimulating hormone, and leptin expression levels in uveal melanoma patient serum and tumor tissues: correlation to disease progression.

Oba J, Esmaeli B, Ellerhorst JA, Lyons GR, Milton DR, Wang WL, Macedo MP, Lazar AJ, Grimm EA, Chattopadhyay C.

Melanoma Res. 2017 Apr;27(2):126-133. doi: 10.1097/CMR.0000000000000329.

PMID:
28118269
2.

Elevated Serum Leptin Levels are Associated With an Increased Risk of Sentinel Lymph Node Metastasis in Cutaneous Melanoma.

Oba J, Wei W, Gershenwald JE, Johnson MM, Wyatt CM, Ellerhorst JA, Grimm EA.

Medicine (Baltimore). 2016 Mar;95(11):e3073. doi: 10.1097/MD.0000000000003073.

3.

Expression of leptin and iNOS in oral melanomas in dogs.

Greene VR, Wilson H, Pfent C, Roethele J, Carwile J, Qin Y, Grimm E, Ellerhorst JA.

J Vet Intern Med. 2013 Sep-Oct;27(5):1278-82. doi: 10.1111/jvim.12169. Epub 2013 Aug 26.

4.

Association of activated c-Met with NRAS-mutated human melanomas.

Chattopadhyay C, Ellerhorst JA, Ekmekcioglu S, Greene VR, Davies MA, Grimm EA.

Int J Cancer. 2012 Jul 15;131(2):E56-65. doi: 10.1002/ijc.26487. Epub 2012 Jan 11.

5.

Clinical correlates of NRAS and BRAF mutations in primary human melanoma.

Ellerhorst JA, Greene VR, Ekmekcioglu S, Warneke CL, Johnson MM, Cooke CP, Wang LE, Prieto VG, Gershenwald JE, Wei Q, Grimm EA.

Clin Cancer Res. 2011 Jan 15;17(2):229-35. doi: 10.1158/1078-0432.CCR-10-2276. Epub 2010 Oct 25. Erratum in: Clin Cancer Res. 2011 Mar 15;17(6):1641.

6.

Promotion of melanoma growth by the metabolic hormone leptin.

Ellerhorst JA, Diwan AH, Dang SM, Uffort DG, Johnson MK, Cooke CP, Grimm EA.

Oncol Rep. 2010 Apr;23(4):901-7.

7.

Autologous tumor-derived heat-shock protein peptide complex-96 (HSPPC-96) in patients with metastatic melanoma.

Eton O, Ross MI, East MJ, Mansfield PF, Papadopoulos N, Ellerhorst JA, Bedikian AY, Lee JE.

J Transl Med. 2010 Jan 29;8:9. doi: 10.1186/1479-5876-8-9.

8.

Genetic deficiency of complement isoforms C4A or C4B predicts improved survival of metastatic renal cell carcinoma.

Zafar GI, Grimm EA, Wei W, Johnson MM, Ellerhorst JA.

J Urol. 2009 Mar;181(3):1028-34; discussion 1034. doi: 10.1016/j.juro.2008.11.013. Epub 2009 Jan 16.

9.

Frequencies of NRAS and BRAF mutations increase from the radial to the vertical growth phase in cutaneous melanoma.

Greene VR, Johnson MM, Grimm EA, Ellerhorst JA.

J Invest Dermatol. 2009 Jun;129(6):1483-8. doi: 10.1038/jid.2008.374.

10.

Lack of maturation with anti-leptin receptor antibody in melanoma but not in nevi.

Diwan AH, Dang SM, Prieto VG, Ellerhorst JA.

Mod Pathol. 2009 Jan;22(1):103-6. doi: 10.1038/modpathol.2008.166. Epub 2008 Oct 3.

11.

NF-kappaB mediates mitogen-activated protein kinase pathway-dependent iNOS expression in human melanoma.

Uffort DG, Grimm EA, Ellerhorst JA.

J Invest Dermatol. 2009 Jan;129(1):148-54. doi: 10.1038/jid.2008.205. Epub 2008 Jul 31.

12.

Changes in pERK1/2 and pAKT expression in melanoma lesions after imatinib treatment.

Hwang CS, Prieto VG, Diwan AH, Lizee G, Ellerhorst JA, Ekmekcioglu S, Liu P, Eton O, Kinney SA, Grimm EA, Hwu P, Kim KB.

Melanoma Res. 2008 Aug;18(4):241-5. doi: 10.1097/CMR.0b013e3283046146.

13.

Constitutive intracellular production of iNOS and NO in human melanoma: possible role in regulation of growth and resistance to apoptosis.

Grimm EA, Ellerhorst J, Tang CH, Ekmekcioglu S.

Nitric Oxide. 2008 Sep;19(2):133-7. doi: 10.1016/j.niox.2008.04.009. Epub 2008 Apr 22.

14.

Human melanoma cells express functional receptors for thyroid-stimulating hormone.

Ellerhorst JA, Sendi-Naderi A, Johnson MK, Cooke CP, Dang SM, Diwan AH.

Endocr Relat Cancer. 2006 Dec;13(4):1269-77.

PMID:
17158770
15.

Tumor iNOS predicts poor survival for stage III melanoma patients.

Ekmekcioglu S, Ellerhorst JA, Prieto VG, Johnson MM, Broemeling LD, Grimm EA.

Int J Cancer. 2006 Aug 15;119(4):861-6.

16.

Galectin-3 regulates mitochondrial stability and antiapoptotic function in response to anticancer drug in prostate cancer.

Fukumori T, Oka N, Takenaka Y, Nangia-Makker P, Elsamman E, Kasai T, Shono M, Kanayama HO, Ellerhorst J, Lotan R, Raz A.

Cancer Res. 2006 Mar 15;66(6):3114-9.

17.

Regulation of iNOS by the p44/42 mitogen-activated protein kinase pathway in human melanoma.

Ellerhorst JA, Ekmekcioglu S, Johnson MK, Cooke CP, Johnson MM, Grimm EA.

Oncogene. 2006 Jun 29;25(28):3956-62. Epub 2006 Feb 13.

PMID:
16474847
18.

Expression of thyrotropin-releasing hormone by human melanoma and nevi.

Ellerhorst JA, Naderi AA, Johnson MK, Pelletier P, Prieto VG, Diwan AH, Johnson MM, Gunn DC, Yekell S, Grimm EA.

Clin Cancer Res. 2004 Aug 15;10(16):5531-6.

19.

HLA class II haplotypes predict favorable outcomes for patients with metastatic RCC.

Ellerhorst JA, Hildebrand WH, Cavett JW, Fernandez-Vina MA, Hodges S, Poindexter N, Fischer H, Grimm EA.

Urologe A. 2004 Sep;43 Suppl 3:S137. No abstract available.

PMID:
15148575
20.

MDA-7/IL-24 is a unique cytokine--tumor suppressor in the IL-10 family.

Chada S, Sutton RB, Ekmekcioglu S, Ellerhorst J, Mumm JB, Leitner WW, Yang HY, Sahin AA, Hunt KK, Fuson KL, Po├Čndexter N, Roth JA, Ramesh R, Grimm EA, Mhashilkar AM.

Int Immunopharmacol. 2004 May;4(5):649-67. Review.

PMID:
15120650
21.

Phase II evaluation of paclitaxel by short intravenous infusion in metastatic melanoma.

Bedikian AY, Plager C, Papadopoulos N, Eton O, Ellerhorst J, Smith T.

Melanoma Res. 2004 Feb;14(1):63-6.

PMID:
15091196
22.

High prevalence of hypothyroidism among patients with cutaneous melanoma.

Ellerhorst JA, Cooksley CD, Broemeling L, Johnson MM, Grimm EA.

Oncol Rep. 2003 Sep-Oct;10(5):1317-20.

PMID:
12883700
23.

Heterozygosity or homozygosity for 2 HLA class II haplotypes predict favorable outcomes for renal cell carcinoma treated with cytokine therapy.

Ellerhorst JA, Hildebrand WH, Cavett JW, Fernandez-Vina MA, Hodges S, Poindexter N, Fischer H, Grimm EA.

J Urol. 2003 Jun;169(6):2084-8.

PMID:
12771724
24.

Negative association of melanoma differentiation-associated gene (mda-7) and inducible nitric oxide synthase (iNOS) in human melanoma: MDA-7 regulates iNOS expression in melanoma cells.

Ekmekcioglu S, Ellerhorst JA, Mumm JB, Zheng M, Broemeling L, Prieto VG, Stewart AL, Mhashilkar AM, Chada S, Grimm EA.

Mol Cancer Ther. 2003 Jan;2(1):9-17.

25.

Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel.

Ibrahim NK, Desai N, Legha S, Soon-Shiong P, Theriault RL, Rivera E, Esmaeli B, Ring SE, Bedikian A, Hortobagyi GN, Ellerhorst JA.

Clin Cancer Res. 2002 May;8(5):1038-44.

26.

Phase II trial of 9-nitrocamptothecin (RFS 2000) for patients with metastatic cutaneous or uveal melanoma.

Ellerhorst JA, Bedikian AY, Smith TM, Papadopoulos NE, Plager C, Eton O.

Anticancer Drugs. 2002 Feb;13(2):169-72.

PMID:
11901310
27.

Loss of MDA-7 expression with progression of melanoma.

Ellerhorst JA, Prieto VG, Ekmekcioglu S, Broemeling L, Yekell S, Chada S, Grimm EA.

J Clin Oncol. 2002 Feb 15;20(4):1069-74.

PMID:
11844832
28.

Effects of galectin-3 expression on growth and tumorigenicity of the prostate cancer cell line LNCaP.

Ellerhorst JA, Stephens LC, Nguyen T, Xu XC.

Prostate. 2002 Jan 1;50(1):64-70.

PMID:
11757037
29.

Autoimmunity and hypothyroidism in patients with uveal melanoma.

Ellerhorst JA, Cooksley CD, Grimm EA.

Melanoma Res. 2001 Dec;11(6):633-7.

PMID:
11725210
30.

Down-regulated melanoma differentiation associated gene (mda-7) expression in human melanomas.

Ekmekcioglu S, Ellerhorst J, Mhashilkar AM, Sahin AA, Read CM, Prieto VG, Chada S, Grimm EA.

Int J Cancer. 2001 Oct 1;94(1):54-9.

31.

Randomized multicenter phase II trial of subcutaneous recombinant human interleukin-12 versus interferon-alpha 2a for patients with advanced renal cell carcinoma.

Motzer RJ, Rakhit A, Thompson JA, Nemunaitis J, Murphy BA, Ellerhorst J, Schwartz LH, Berg WJ, Bukowski RM.

J Interferon Cytokine Res. 2001 Apr;21(4):257-63.

PMID:
11359657
32.

Phase II evaluation of bryostatin-1 in metastatic melanoma.

Bedikian AY, Plager C, Stewart JR, O'Brian CA, Herdman SK, Ross M, Papadopoulos N, Eton O, Ellerhorst J, Smith T.

Melanoma Res. 2001 Apr;11(2):183-8.

PMID:
11333129
33.

Whole brain irradiation for patients with metastatic melanoma: a review of 87 cases.

Ellerhorst J, Strom E, Nardone E, McCutcheon I.

Int J Radiat Oncol Biol Phys. 2001 Jan 1;49(1):93-7.

PMID:
11163501
34.

Inducible nitric oxide synthase and nitrotyrosine in human metastatic melanoma tumors correlate with poor survival.

Ekmekcioglu S, Ellerhorst J, Smid CM, Prieto VG, Munsell M, Buzaid AC, Grimm EA.

Clin Cancer Res. 2000 Dec;6(12):4768-75.

35.

A phase II evaluation of bexarotene (Targretin) capsules in patients with metastatic melanoma.

Bedikian AY, Plager C, Papadopoulos N, Ellerhorst J, Smith T, Benjamin RS.

Oncol Rep. 2000 Jul-Aug;7(4):883-6.

PMID:
10854563
36.

Phase I-II study of gamma interferon and 5-fluorouracil for patients with metastatic renal cell carcinoma

DeLima M, Amato RJ, Jackson A, Tu SM, Banks M, Finn L, Ellerhorst J.

Cancer Biother Radiopharm. 1997 Dec;12(6):365-70.

PMID:
10851489
37.

A phase II study of "decrescendo" interleukin-2 plus interferon-alpha-2a in patients with progressive metastatic melanoma after chemotherapy.

Eton O, Buzaid AC, Bedikian AY, Smith TM, Papadopoulos NE, Ellerhorst JA, Hibberts JL, Legha SS, Benjamin RS.

Cancer. 2000 Apr 1;88(7):1703-9.

PMID:
10738230
38.

Melanoma metastatic to the spine: a review of 133 cases.

Gokaslan ZL, Aladag MA, Ellerhorst JA.

Melanoma Res. 2000 Feb;10(1):78-80.

PMID:
10711643
39.

Galectin-1 and galectin-3 expression in human prostate tissue and prostate cancer.

Ellerhorst J, Troncoso P, Xu XC, Lee J, Lotan R.

Urol Res. 1999 Oct;27(5):362-7.

PMID:
10550525
40.

Phase II trial of doxil for patients with metastatic melanoma refractory to frontline therapy.

Ellerhorst JA, Bedikian A, Ring S, Buzaid AC, Eton O, Legha SS.

Oncol Rep. 1999 Sep-Oct;6(5):1097-9.

PMID:
10425308
41.

Induction of differentiation and apoptosis in the prostate cancer cell line LNCaP by sodium butyrate and galectin-1.

Ellerhorst J, Nguyen T, Cooper DN, Estrov Y, Lotan D, Lotan R.

Int J Oncol. 1999 Feb;14(2):225-32.

PMID:
9917496
42.
43.

Phase II trial of alternating weekly chemohormonal therapy for patients with androgen-independent prostate cancer.

Ellerhorst JA, Tu SM, Amato RJ, Finn L, Millikan RE, Pagliaro LC, Jackson A, Logothetis CJ.

Clin Cancer Res. 1997 Dec;3(12 Pt 1):2371-6.

44.
45.

Timely delivery of biological therapy after cytoreductive nephrectomy in carefully selected patients with metastatic renal cell carcinoma.

Levy DA, Swanson DA, Slaton JW, Ellerhorst J, Dinney CP.

J Urol. 1998 Apr;159(4):1168-73.

PMID:
9507824
46.

Coincident renal cell carcinoma and nonHodgkin's lymphoma: the M. D. Anderson experience and review of the literature.

Anderson CM, Pusztai L, Palmer JL, Cabanillas F, Ellerhorst JA.

J Urol. 1998 Mar;159(3):714-7. Review.

PMID:
9474132
47.

Phase II trial of 5-fluorouracil, interferon-alpha and continuous infusion interleukin-2 for patients with metastatic renal cell carcinoma.

Ellerhorst JA, Sella A, Amato RJ, Tu SM, Millikan RE, Finn LD, Banks M, Logothetis CJ.

Cancer. 1997 Dec 1;80(11):2128-32.

PMID:
9392335
48.

Hyperplasia of axillary nodes in patients undergoing immunotherapy.

Loyer E, David C, Sella A, Ellerhorst J.

AJR Am J Roentgenol. 1997 Nov;169(5):1359-62.

PMID:
9353459
49.

Effect of decreased plasma low-density lipoprotein levels on adrenal and testicular function in man.

Arem R, Ghusn H, Ellerhorst J, Comstock JP.

Clin Biochem. 1997 Jul;30(5):419-24.

PMID:
9253519
50.

Strontium-89 combined with doxorubicin in the treatment of patients with androgen-independent prostate cancer.

Tu SM, Delpassand ES, Jones D, Amato RJ, Ellerhorst J, Logothetis CJ.

Urol Oncol. 1996 Nov-Dec;2(6):191-7.

PMID:
21224168

Supplemental Content

Loading ...
Support Center